arrow
G

Gheath Alatrash

university of texas system
H指数:39
被引数:7,358

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center

吉达西他滨在移植后高风险急性髓系白血病和骨髓增生异常综合征患者中改善了无复发生存期:单中心II期研究结果

2026-01-010
OA
Ex Vivo Mesenchymal Progenitor Cell-based Cord Blood Cell Expansion and Exofucosylation to Enhance Transplant Engraftment

离体间充质祖细胞介导的脐带血细胞扩增及外岩藻糖基化,以增强移植植入效果

2025-11-190
PRE
Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

作者更正:造血干细胞自体移植后的克隆性进化

2025-08-110
OAAI
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

自体干细胞移植后造血干细胞的克隆进化

2025-07-010
OA
T cell receptor mimic CAR T cells targeting cathepsin G signal peptide

靶向cathepsin G信号肽的T细胞受体模拟CAR T细胞

LEUKEMIA
IF13.4
2025-05-280
PRE
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer

卡博赞替尼和纳武利尤单抗治疗复发性子宫内膜癌的免疫学应答和耐药生物标志物

2025-02-250
OA
Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality

造血干细胞移植后的限制性通气缺陷与死亡率增加有关

2025-02-010
PRE
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

异基因造血干细胞移植在CAR T疗法后应用于复发/难治性急性淋巴细胞白血病

BLOOD
IF23.1
2024-11-051
PRE
Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

培美曲塞联合阿扎胞苷和维奈克拉用于急性髓系白血病患者的疗效与安全性:一项研究者发起、多中心、CTEP资助的随机、Ⅱ期试验(BLAST AML-2)的结果

BLOOD
IF23.1
2024-11-050
PRE
CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen and Potent Antileukemic In Vivo

CBX250是一种新型组织蛋白酶G肽-HLA靶向的T细胞结合剂,具有高肿瘤抗原性并在体内表现出强大的抗白血病活性。

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

靶向MCL1-driven抗凋亡途径克服了慢性粒单核细胞白血病中低甲基化剂失败后的爆炸进展

2024-06-013
OAAI
Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia
2024-03-221
PRE
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation
2024-02-291
OAAI
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
2024-02-017
PRE
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation
2024-02-013
PRE